jcp Videos

Videos

Insights from CPC+CBEx 2023

01/18/2024

John Hennessy, MBA, details his highlights from CPC+CBEx 2023 and answers questions related to cancer care, industry consolidation, and the future of cancer care at home.

John Hennessy, MBA, details his...

01/18/2024

Journal of Clinical Pathways

Videos

Outcomes of Men With High-Risk, Biochemically Recurrent Prostate Cancer Who Discontinued Enzalutamide Monotherapy in the EMBARK Study

01/18/2024

Neal Shore , MD, FACS;

Neal Shore, MD, FACS, discusses his study on the outcomes of men with high-risk, biochemically recurrent prostate cancer who suspended enzalutamide monotherapy treatment in the phase 3 EMBARK study.

Neal Shore, MD, FACS, discusses...

01/18/2024

Journal of Clinical Pathways

Videos

Trends in the Rising Costs of Care Among Self-Insured Employers

01/11/2024

Frederick M. Schnell , MD, FACP;

Frederick M. Schnell, MD, FACP, discusses the rising costs of cancer care for self-insured employers and how they can partner with cancer centers to continue to provide high-value care despite the cost increases.

Frederick M. Schnell, MD, FACP,...

01/11/2024

Journal of Clinical Pathways

Conference Coverage

Recent Breakthroughs in the Mantle Cell Lymphoma Treatment Landscape

01/08/2024

Bijal D. Shah , MD;

Bijal D. Shah, MD, shares the breakthroughs in the mantle cell lymphoma treatment landscape that he found most promising at the 65th American Society of Hematology (ASH) Annual Meeting.

Bijal D. Shah, MD, shares the...

01/08/2024

Oncology

Conference Coverage

Examining Predictors of Emergent Thrombocytopenia After Ruxolitinib Treatment Among Patients With Myelofibrosis

01/03/2024

Douglas Tremblay , MD;

At the 2023 ASH Annual Meeting, Douglas Tremblay, MD, discussed the prevalence and predictors of emergent thrombocytopenia following ruxolitinib treatment among patients with myelofibrosis.

At the 2023 ASH Annual Meeting,...

01/03/2024

Oncology

Videos

The Impact of Racial and Socioeconomic Disparities in Patients With Chronic Lymphocytic Leukemia

01/02/2024

Ira Zackon , MD;

Ira Zackon, MD, New York Oncology Hematology, speaks with the Journal of Clinical Pathways about the abstract he presented at the 2023 ASH Annual Meeting & Exposition titled “Racial and Socioeconomic Disparities Among Patients with Chronic...

Ira Zackon, MD, New York...

01/02/2024

Journal of Clinical Pathways

Videos

Strategies the Health Care Industry Can Implement to Improve Black Women’s Participation in Clinical Trials

12/28/2023

Kianta Key ;

Kianta Key, Group Senior Vice President for GCI Health, explained the different influences and societal factors for why Black women are underrepresented in clinical trials and how the health care industry can create changes to diversify...

Kianta Key, Group Senior Vice...

12/28/2023

Journal of Clinical Pathways

Videos

Increasing Biomarker Testing Rates for Patients With NSCLC

12/07/2023

David Waterhouse , MD, MPH;

David Waterhouse, MD, MPH, talks about OHC’s quality improvement project that increased biomarker testing rates for patients with metastatic NSCLC, and shared how the program can be scaled to other practices and other cancers.

David Waterhouse, MD, MPH, talks...

12/07/2023

Journal of Clinical Pathways

Videos

Players and Disruptors in Health Care Industry Consolidation

12/05/2023

Ronald Barkley , MS, JD;

Ronald Barkley, MS, JD, Cancer Center Business Development Group, provides an overview of the current consolidation of the health care industry and the major players and disruptors leading this transformation.

Ronald Barkley, MS, JD, Cancer...

12/05/2023

Cancer Care Business Exchange

Todd Schonherz, American Oncology Network

Videos

Healthcare Industry Consolidation And What This Means For Community Oncology Practices

11/21/2023

Todd Schonherz ;

Todd Schonherz, CEO of American Oncology Network, details his session on the impact that industry consolidation has had on community oncology practices at CPC+CBEx 2023.

Todd Schonherz, CEO of American...

11/21/2023

Journal of Clinical Pathways

Current Issue

October 2024

Volume 10

Issue 5

Current Issue

Issue Archive

Special Reports

Sponsored

JCP Special Report

The Value of Tissue-Based Genomic Profiling in Oncology

09/17/2024

Innovations in precision oncology have helped healthcare providers to create more personalized treatment plans and improve patient outcomes. View this special report to learn more.

Innovations in precision...

09/17/2024

Journal of Clinical Pathways

Sponsored

Special Report

Shedding Light on Non-Small Cell Lung Cancer & Its Impact on Patients

04/03/2023

This supplement aims to raise awareness about non-small cell lung cancer (NSCLC) and its impact on patients by providing comprehensive information to help improve early detection and appropriate care.

This supplement aims to raise...

04/03/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

Brukinsa® (Zanubrutinib) for Chronic Lymphocytic Leukemia

03/31/2023

In this product monograph, read an interview with Jeff P. Sharman, MD, as he discusses important BRUKINSA® trial data including efficacy, safety, dosing, administration, and other relevant data. These key findings supported the Food and Drug...

In this product monograph, read...

03/31/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

Tumor Lysis Syndrome: Early Diagnosis and Management

01/04/2023

This review summarizes the diagnosis, pathophysiology, and evidence-based guidelines for the prevention and management of tumor lysis syndrome, a common, acute, life-threatening disease primarily in patients with hematologic cancers and solid...

This review summarizes the...

01/04/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

A Tumor Lysis Syndrome Risk Assessment and Its Impact on Patients

08/09/2022

In an interview with Journal of Clinical Pathways, Nicholas Short, MD, shares objectives on the design and benefits of MD Anderson’s Tumor Lysis Syndrome clinical assessment for patient risk and impact on patient care.

In an interview with Journal of...

08/09/2022

Journal of Clinical Pathways

Updated NCCN Guidelines on B-Cell Lymphomas

Sponsored

JCP Special Report

Overview of the Updated NCCN Guidelines on B-Cell Lymphomas

06/15/2022

Robert Fee ;

Updated multiple times in 2022, the National Comprehensive Cancer Network (NCCN) Guidelines for B-Cell Lymphomas provide recommendations for the prevention, diagnosis, and management of malignancies.

Updated multiple times in 2022,...

06/15/2022

Journal of Clinical Pathways

Sponsored

Special Report

Expanded Indication for Zanubrutinib: Marginal Zone Lymphoma and Waldenström’s Macroglobulinemia

06/10/2022

In an interview with Journal of Clinical Pathways, Mitul Gandhi, MD, reviews the clinical impact and treatment approaches and challenges for patients with marginal zone lymphoma and Waldenström’s macroglobulinemia.

In an interview with Journal of...

06/10/2022

Journal of Clinical Pathways

JCP Special Report

Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group

05/20/2022

Robin T. Zon , MD, FACP, FASCO;

Gordon Kuntz ;

Winston Wong , PharmD;

The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...

The Journal of Clinical Pathways...

05/20/2022

Journal of Clinical Pathways

Overview of the Updated NCCN Guidelines on Triple-Negative Breast Cancer

Sponsored

Special Report

Overview of the Updated NCCN Guidelines on Triple-Negative Breast Cancer

12/15/2021

Deborah Abrams Kaplan ;

NCCN released updates to its practice guidelines on treating triple-negative breast cancer, featuring updates on sacituzumab govitecan recommendations and more.

NCCN released updates to its...

12/15/2021

Journal of Clinical Pathways

Sponsored

Special Report

Navigating the Patient Journey for Unresectable Stage III Non-Small Cell Lung Cancer

09/16/2021

.ryan-test { display: none; } .body-content h3 { font-size: 18px; line-height: 18px; color: #000000; font-weight: 600px; } .related-content { display: none; } .body-content div > div:nth-of-type(3) .paragraph > h3 >...

.ryan-test { display:...

09/16/2021

Journal of Clinical Pathways

Journal of Clinical Pathways Newsletter

Videos

Current Issue

Special Reports

Subscribe

Specialties

Events

Year Round Education

HMP Global Products